297 related articles for article (PubMed ID: 15920546)
21. Expression of glypican-3 in undifferentiated embryonal sarcoma and mesenchymal hamartoma of the liver.
Levy M; Trivedi A; Zhang J; Miles L; Mattis AN; Kim GE; Lassman C; Anders RA; Misdraji J; Yerian LM; Xu H; Dhall D; Wang HL
Hum Pathol; 2012 May; 43(5):695-701. PubMed ID: 21937079
[TBL] [Abstract][Full Text] [Related]
22. Expression of a glypican-related 62-kDa antigen is decreased in hepatocellular carcinoma in correspondence to the grade of tumor differentiation.
Lage H; Kellner U; Tannapfel A; Dietel M
Virchows Arch; 2001 Jun; 438(6):567-73. PubMed ID: 11469688
[TBL] [Abstract][Full Text] [Related]
23. Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver: an immunocytochemical study.
Ligato S; Mandich D; Cartun RW
Mod Pathol; 2008 May; 21(5):626-31. PubMed ID: 18264086
[TBL] [Abstract][Full Text] [Related]
24. A novel panel of biomarkers in distinction of small well-differentiated HCC from dysplastic nodules and outcome values.
Jin GZ; Dong H; Yu WL; Li Y; Lu XY; Yu H; Xian ZH; Dong W; Liu YK; Cong WM; Wu MC
BMC Cancer; 2013 Mar; 13():161. PubMed ID: 23537217
[TBL] [Abstract][Full Text] [Related]
25. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.
Coston WM; Loera S; Lau SK; Ishizawa S; Jiang Z; Wu CL; Yen Y; Weiss LM; Chu PG
Am J Surg Pathol; 2008 Mar; 32(3):433-44. PubMed ID: 18300806
[TBL] [Abstract][Full Text] [Related]
26. Roles of Combined Glypican-3 and Glutamine Synthetase in Differential Diagnosis of Hepatocellular Lesions.
Wasfy RE; Shams Eldeen AA
Asian Pac J Cancer Prev; 2015; 16(11):4769-75. PubMed ID: 26107238
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver.
Ibrahim TR; Abdel-Raouf SM
Pathol Oncol Res; 2015 Apr; 21(2):379-87. PubMed ID: 25108409
[TBL] [Abstract][Full Text] [Related]
28. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders.
Zhu ZW; Friess H; Wang L; Abou-Shady M; Zimmermann A; Lander AD; Korc M; Kleeff J; Büchler MW
Gut; 2001 Apr; 48(4):558-64. PubMed ID: 11247902
[TBL] [Abstract][Full Text] [Related]
29. High-affinity monoclonal antibodies to cell surface tumor antigen glypican-3 generated through a combination of peptide immunization and flow cytometry screening.
Phung Y; Gao W; Man YG; Nagata S; Ho M
MAbs; 2012; 4(5):592-9. PubMed ID: 22820551
[TBL] [Abstract][Full Text] [Related]
30. Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma.
Tremosini S; Forner A; Boix L; Vilana R; Bianchi L; Reig M; Rimola J; Rodríguez-Lope C; Ayuso C; Solé M; Bruix J
Gut; 2012 Oct; 61(10):1481-7. PubMed ID: 22287594
[TBL] [Abstract][Full Text] [Related]
31. The diagnostic value of hepatocyte paraffin antibody 1 in differentiating hepatocellular neoplasms from nonhepatic tumors: a review.
Lamps LW; Folpe AL
Adv Anat Pathol; 2003 Jan; 10(1):39-43. PubMed ID: 12502967
[TBL] [Abstract][Full Text] [Related]
32. Glypican 3 expression in pediatric malignant solid tumors.
Kinoshita Y; Tanaka S; Souzaki R; Miyoshi K; Kohashi K; Oda Y; Nakatsura T; Taguchi T
Eur J Pediatr Surg; 2015 Feb; 25(1):138-44. PubMed ID: 25344940
[TBL] [Abstract][Full Text] [Related]
33. Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma.
Yan B; Wei JJ; Qian YM; Zhao XL; Zhang WW; Xu AM; Zhang SH
Ann Diagn Pathol; 2011 Jun; 15(3):162-9. PubMed ID: 21371925
[TBL] [Abstract][Full Text] [Related]
34. Clinical application of specific antibody against glypican-3 for hepatocellular carcinoma diagnosis.
Yu J; Ma Q; Zhang B; Ma R; Xu X; Li M; Xu W; Li M
Sci China Life Sci; 2013 Mar; 56(3):234-9. PubMed ID: 23526389
[TBL] [Abstract][Full Text] [Related]
35. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study.
Zhang L; Liu H; Sun L; Li N; Ding H; Zheng J
Acta Histochem; 2012 Oct; 114(6):547-52. PubMed ID: 22119409
[TBL] [Abstract][Full Text] [Related]
36. Development of a Time-Resolved Fluorescence Immunoassay for the Diagnosis of Hepatocellular Carcinoma Based on the Detection of Glypican-3.
Chen JJ; Xie CM; Wang CR; Wan Y; Dong ZN; Li M; Xu WW
J Fluoresc; 2017 Jul; 27(4):1479-1485. PubMed ID: 28429175
[TBL] [Abstract][Full Text] [Related]
37. Current methods for the detection of glypican-3.
Xiao X; Huang Q; Lin X; Zahid KR; Huang X; Liu T; Zeng T
Anal Methods; 2024 Jan; 16(2):152-160. PubMed ID: 38108085
[TBL] [Abstract][Full Text] [Related]
38. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary.
Esheba GE; Pate LL; Longacre TA
Am J Surg Pathol; 2008 Apr; 32(4):600-7. PubMed ID: 18277882
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
[TBL] [Abstract][Full Text] [Related]
40. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
Nassar A; Cohen C; Siddiqui MT
Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
